Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
As the SELECT trial nears completion, a similar large trial was launched in autumn 2022, but this one involves a new wrinkle on GLP-1 receptor agonism that appears to yield even greater weight loss
16(5): 555949.DOI: 10.19080/CRDOJ.2023.16.555949 Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Abstract Retatrutide is a triple hormone agonist of the receptors of glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon that can be administered subcutaneously once a week
L-cysteine containing vitamin supplement which prevents or alleviates alcohol-related hangover symptoms: Nausea, Headache, stress and anxiety
An imbalance between antioxidants and ROS results in the formation of free radicals that lead to cellular damage
The Future of Weight Loss: What You Need to Know About the New Once-Daily Pills The next generation of UK weight loss medications: once-daily pills, MHRA licensing of the Wegovy pill, and how to check your eligibility through PrivateDoc
